ABSTRACT: The development of glucocorticoid (GC) resistance is a serious problem that complicates the treatment of immune-related diseases, such as asthma, ulcerative colitis, and hematologic cancers. hGR␣ and hGR␤ are two isoforms of the human glucocorticoid receptor, which differ in the structural composition of the carboxy-terminal end of the ligand-binding domain and therefore in their ability to bind glucocorticoid ligand and in their physiological function. hGR␣ is the classically functional GR, while hGR␤ seems to act mainly as a dominant negative to the function of hGR␣. Because of the ability of hGR␤ to antagonize the action of hGR␣, it has been hypothesized that changes in the expression of hGR␤ may underlie the development of glucocorticoid resistance. In this article we review what is known about the expression and physiological action of hGR␤ in normal cells and tissue as well as in several disease states. Taken together, the evidence suggests that the ratio of hGR␣:hGR␤ expression is indeed critical to the glucocorticoid responsiveness of various cells. This ratio can be altered by changing the expression level of hGR␣, hGR␤, or both receptors simultaneously. Higher ratios correlate with glucocorticoid sensitivity, while lower ratios correlate with glucocorticoid resistance. Thus hGR␤ can be an important modulator of glucocorticoid responsiveness.
INTRODUCTION
Glucocorticoids (GC) are a class of naturally occurring and synthetic steroid hormones that affect virtually every aspect of human physiology. Their actions include important roles in the development of the lung and nervous system, [1] [2] [3] the modulation of skeletal metabolism, 4 the maintenance of homeostasis, [5] [6] [7] and the modulation/regulation of behavior. [8] [9] [10] [11] [12] Perhaps their most important effects, however, are highly effective anti-inflammatory and immunomodulatory actions that are exploited in the treatment of such diseases as arthritis, asthma, allergic rhinitis, and leukemia/lymphoma. [13] [14] [15] [16] [17] [18] The broad involvement of glucocorticoids in both normal and pathologic physiological processes makes them one of the most important and commonly prescribed classes of drugs available, 19 but also underlies the side effects commonly experienced with glucocorticoid treatment. 20, 21 In particular, the development of glucocorticoid resistance is a serious complication that can occur during chemotherapy regimens for hematologic cancers and chronic asthma therapy, making treatment of those conditions more difficult. 22, 23 The mechanisms that underlie the development of glucocorticoid resistance are poorly understood and likely vary with disease type, treatment regimen, and the genetic background of the patient. However, an increasing number of reports indicate that changes in the relative expression of the glucocorticoid receptor (GR) isoforms hGR␣ and hGR␤ are associated with glucocorticoid resistance, and may contribute to its development. Here, we review what is known about hGR␤ and its relationship to glucocorticoid resistance.
GLUCOCORTICOID RECEPTOR ␣ AND ␤: STRUCTURAL DIFFERENCES
Glucocorticoid actions are mediated by the glucocorticoid receptor, which is a member of the large steroid/thyroid/retinoic acid receptor superfamily that regulates gene transcription in a ligand-dependent manner. The gene for human GR (hGR) was originally cloned in 1985. 24 It is located on chromosome 5 (region 5q31) 25, 26 and consists of nine exons. 24, 27 Through alternative splicing of exon 9, two isoforms of the hGR gene, hGR␣ and hGR␤, are produced. 28 The nuclear receptor superfamily has a common, modular domain structure that includes a variable-length amino terminus, a centrally located, zinc-finger DNA-binding domain (DBD), and a carboxy terminus ligand-binding domain (LBD). 19, 29 In addition to these domains, GR has two transcription-activating regions, one in the amino terminal domain of the protein (AF-1 or 1) that appears to act somewhat independently of ligand binding, and a second in the ligand-binding domain (AF-2 or 2) whose function is dependent on ligand binding. 30, 31 Additionally, the hGR LBD contains nuclear localization signals and sites for interaction with other transcription factors, cofactors, and protein chaperones. [32] [33] [34] Analysis of the crystal structure of the hGR␣ LBD indicates that it is a 12-helix bundle consisting of three layers, with the ligand-binding pocket located in the center. 35 Comparison of the GR LBD structure with the LBD structures of other nuclear receptors suggests that the ligand-dependent conformation of the final, 12th helix is critical to the AF-2 transactivation function of GR. 36, 37 The alternately spliced exon 9 of the hGR coding sequence encodes the extreme carboxy terminal end of the GR ligand-binding domain, as well as the 3 UTR. Thus the hGR␣ and ␤ isoforms are identical proteins up through amino acid 727 corresponding to the C-terminal end of helix 10 of the LBD, but the remainder of the ligand-binding domain differs between the two receptors. hGR␣ has an additional 50 amino acids that encode helices 11 and 12 to complete a functional domain capable of binding ligand and transactivating gene expression. In contrast, hGR␤ has only an additional 15 distinct amino acids. Consequently, hGR␤ is missing helix 12 of the ligand-binding domain and possesses a unique sequence in helix 11 when compared to hGR␣. The shortened, distinct LBD of hGR␤ is reported to be unable to bind ligand, 24, 28, 30 resulting in a receptor that is unable to directly activate glucocorticoid responsive promoters. 24, 30 Sequential mutation of the 15 unique amino acids within the hGR␤ LBD suggests that amino acids 733 and 734 (unique amino acids 6 and 7) play an important role in determining the biological activity of hGR␤.
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GLUCOCORTICOID RECEPTOR ␣ AND ␤: FUNCTIONAL DIFFERENCES
Because the ␣ isoform of hGR binds ligand and affects gene expression, while the ␤ isoform does not, far more is known about the mechanisms of hGR␣ than hGR␤ action. In the absence of ligand, hGR␣ is maintained in the cytoplasm in a multiprotein complex that includes heat-shock protein 90 and several immunophilins. Upon ligand binding, this complex dissociates, exposing the nuclear localization signal of hGR␣ and allowing it to translocate to the nucleus. Once in the nucleus, hGR␣ affects gene transcription, either by binding to specific DNA elements known as glucocorticoid response elements (GRE), or by protein-protein interactions with other transcription factors, such as AP-1, NF-B, or STAT family members.
In contrast, hGR␤ is found constitutively in the nucleus and is not thought to bind ligand. 28, 39 In addition, hGR␤ cannot affect gene expression by itself. Instead, evidence suggests that hGR␤ may act as a dominant negative to repress the transcriptional activity of hGR␣. Reporter gene experiments carried out using exogenously expressed hGR␣ and hGR␤ in cells that do not express endogenous GR have shown that (1) hGR␤ is not able to activate reporter gene expression by itself 28, 40 and (2) when hGR␤ is overexpressed relative to hGR␣, hGR␤ represses the transcriptional activity of hGR␣. 40, 41 In addition, exogenous expression of hGR␤ can repress the activity of transiently transfected reporter genes driven by endogenous hGR␣ expression. 28 It is believed that hGR␤'s dominant negative activity is the combined result of (1) differences in the identity of amino acid residues 733 and 734 between the hGR␣ and hGR␤ LBDs, which cause hGR␤'s Helix 11 to be disordered, and (2) the constitutively nuclear localization of the hGR␤ receptor. 38 The dominant negative activity of hGR␤ in cell culture has led to the hypothesis that changes in hGR␤ expression relative to hGR␣ could underlie the development of glucocorticoid (GC) resistance in several human diseases. This hypothesis has been partially tested in cell culture using HeLa S 3 cells that express endogenous hGR. It has been demonstrated in these cells that hGR␤ protein levels increase in response to treatment with the proinflammatory cytokine tumor necrosis factor ␣ (TNF-␣). 42 This increase was correlated with the development of GC resistance in these cells, as measured by reporter gene assay. A more direct test of the idea that hGR␤ expression underlies GC resistance comes from a study in which mouse hybridoma cells, which are naturally devoid of the GR␤ isoform, were virally transduced with cDNA for hGR␤. 43 The proliferation of these cells was then compared to nontransduced cells in the presence of hydrocortisone. In contrast to the nontransduced cells, the cells that expressed hGR␤ were resistant to the antiproliferative effects of hydrocortisone. Although these studies do not prove that increased expression of hGR␤ directly underlies glucocorticoid resistance in humans, they do provide evidence that such expression could contribute to this desensitized state of hormone responsiveness. Consequently, there have been a number of investigations into the expression of hGR␤ in disease states that have become GC resistant.
EXPRESSION OF HGR␤ IN NORMAL AND DISEASED CELLS AND TISSUE
The distribution of hGR␤ has been examined in both normal and diseased human cells and tissues, as well as in a number of human cell lines. However, direct comparisons of the levels of the hGR␣ and hGR␤ isoforms, especially for protein expression in normal tissues, have not been done as often or as rigorously as one would like. In addition, few attempts have been made to analyze the expression of hGR␤ in different cell types within the same organ (e.g., neurons vs. glia in brain tissue). Therefore, the actual extent of hGR␣ versus ␤ expression in both normal and diseased cells and tissues is in many cases still unclear. Having said that, the mRNA for hGR␤ has been found in almost every normal human tissue and cell type examined, including adult brain, lung, liver, heart, placenta, skeletal muscle, kidney, pituitary, pancreas, thymus, spleen, bone marrow, nasal mucosa, abdominal fat, leukocytes, eosinophils, peripheral blood mononuclear cells (PBMCs), macrophages, and neutrophils, as well as fetal brain, lung, and liver. 28, 40, 44 In contrast, hGR␤ protein has been shown to have a more restricted distribution. Most frequently, hGR␤ protein has been found in normal T lymphocytes, macrophages, neutrophils, eosinophils, and PBMCs. [45] [46] [47] In addition, hGR␤ protein has been reported in brain, lung, and heart tissue, 39 although there is a contradictory report. 44 Finally, human lung carcinoma, breast carcinoma, endometrial carcinoma, and bladder carcinoma cell lines, as well as HeLa S 3 cervical carcinoma cells, CEM-C7 leukemia cells, JAR choriocarcinoma cells, HEK-293 embryonic kidney cells, and normal lung epithelial cells have all been shown to express hGR␤ protein. 39 The expression of hGR␤ in diseased tissue has been studied primarily in the context of GC-resistant forms of asthma, ulcerative colitis, nasal polyposis, and leukemia, including chronic lymphocytic and acute lymphoblastic leukemias. Of these, GC-resistant chronic asthma has been the most extensively studied. Increased numbers of hGR␤ immunoreactive PBMCs and CD3+ T cells from the airways of patients with GC-resistant versus GC-sensitive asthma have been reported. 45, 48 Extending these findings, greater numbers of hGR␤ immunoreactive cells, primarily CD3+ T cells, have also been found in the lungs of fatal asthma cases as compared to cases of emphysema, mild asthma, or normal subjects. 49 Furthermore, using a cutaneous tuberculin inflammation model, the expression of hGR␤ was greater in T cells and macrophages from GCresistant versus GC-sensitive asthma patients. 50 Taken together, these reports suggest that increased expression of hGR␤ in inflammatory cells, especially T cells, may be related to the development of GC-insensitive asthma.
Three studies have examined the expression of hGR␤ in GC-resistant forms of ulcerative colitis. Two of these studies, examining hGR␣ and ␤ mRNA expression in PBMCs from patients with ulcerative colitis versus normal subjects, found that PBMCs from patients with active ulcerative colitis were more likely to express hGR␤ mRNA. 51, 52 In addition, quantitative comparison of hGR␤ mRNA levels in PBMCs from patients with GC-resistant versus GCsensitive ulcerative colitis revealed higher expression of hGR␤ mRNA in the GC-resistant cases. Furthermore, examination of hGR␤ mRNA levels longitudinally in patients whose ulcerative colitis relapsed revealed increased hGR␤ levels during the relapse. 52 There was no difference in the expression of hGR␣ mRNA between normal subjects and any of the ulcerative colitis patients in these studies. Finally, examination of hGR␤ protein levels in PBMCs by Western blot and in colonic mucosal cells by immunocytochemistry confirmed increased expression of hGR␤ in GC-resistant versus GC-sensitive ulcerative colitis. 51, 53 Taken together, these studies suggest that increased expression of hGR␤ in inflammatory cells is predictive of GC resistance, which is reduced patient response to GC treatment, in ulcerative colitis.
The expression of hGR␤ protein in inflammatory cells found in nasal polyps as opposed to normal middle olfactory turbinate tissue has also been examined. 47 This study found increased hGR␤ expression in nasal polyp inflammatory cells, particularly in T cells, eosinophils, and macrophages. Furthermore, although the number of subjects was small, an inverse correlation was noted between the baseline level of hGR␤ expression and the response to the glucocorticoid fluticasone propionate. High levels of hGR␤ expression correlated with a poor response to treatment with fluticasone propionate.
Finally, hGR␤ expression associated with GC resistance has been examined in several cases of leukemia. The first such report concerned the relative expression of hGR␣ and ␤ isoforms in a single case of GC-resistant chronic lymphocytic leukemia. 54 In cultured lymphocytes from this patient, the level of hGR␣ protein was found to be severely reduced and the level of hGR␤ protein was elevated, resulting in a 20-fold excess of hGR␤ compared to hGR␣. A second report examined the relative levels of hGR␣ and ␤ in 13 cases of acute lymphoblastic leukemia (ALL), including 8 ALL cases with pre-B cell lineage and 5 ALL cases with T cell lineage versus EBV-transformed lymphocytes from normal controls. 55 This study found no changes in the expression of hGR␤ protein in ALL versus normal controls, but did find significant decreases in the expression of hGR␣ protein, especially in the T cell lineage ALL cells. As a result, the ratio of hGR␣:hGR␤ expression was reduced, from 1.4 in controls to 0.86 in ALL with pre-B lineage, and to 0.09 in ALL with T cell lineage. Interestingly, lymphoblasts of the T cell lineage are known to have reduced GC sensitivity. 56 A similar study also correlated the ratio of hGR␤:hGR␣ to ALL-phenotype and GC sensitivity. 57 In that study, hGR␤:hGR␣ ratios were lower in cases of pre-B ALL, which responds well to GC treatment, compared to other types of ALL, which have with a poorer prognostic phenotype and response to GC treatment. Taken together, the results of these studies indicate that the relative expression of hGR␣ to hGR␤ in leukemia cells correlates with their sensitivity to GCs. Lymphoblasts/lymphocytes with lower hGR␣:hGR␤ ratios are less sensitive to the apoptosis-inducing effects of GC treatment and are associated with a poorer prognosis.
When the results of all these studies on hGR␤ expression in different disease states are taken together, a picture begins to emerge in which a reduction in the relative expression of hGR␣:hGR␤ protein is associated with a poor response to GC treatment. Thus decreased expression of hGR␣ and/or increased expression of hGR␤ in inflammatory cells appears to be a common mechanism for the development of glucocorticoid resistance in multiple organs.
CONCLUSIONS
There is general agreement that the expression of hGR␣ is much greater than the expression of hGR␤ in most cells and tissues, in both normal and diseased states. Consequently, there is some disagreement as to whether hGR␤ makes an important contribution to either normal or disease physiology. Some authors have argued that, with such low starting levels, small increases in hGR␤ expression are unlikely to be physiologically relevant because they cannot substantially affect the hGR␣:hGR␤ ratio. However, it has been demonstrated for a growing number of immune-related disease states that decreases in the expression of hGR␣ and/or increases in the expression of hGR␤ do result in substantial changes to the hGR␣:hGR␤ ratio and are correlated with the development of GC resistance. When taken together, these results suggest that hGR␤ does have an important role to play in the development of GC resistance. Thus, even if we do not currently understand the mechanistic details, hGR␤ is potentially a key modulator of the progression of certain immune-related diseases. It is up to future investigators to determine the mechanisms of hGR␤ function in both normal and disease states.
